MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status

British Journal of Cancer

Volumn 72, Issue 4, 1995, Pages 883-888

  Foulkes, W D ^a,b   Stamp, G W H ^c   Afzal, S ^c   Lalani, N ^c   McFarlane, C P ^d   Trowsdale, J ^b   Campbell, I G ^e  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Immunohistochemistry; Mdm2; Mutation; Ovarian cancer; Tp53

Indexed keywords

ANTIBODY; CELL PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GLIOMA; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; PRIORITY JOURNAL; SARCOMA; SOMATIC MUTATION; SOUTHERN BLOTTING;

CHROMOSOME DELETION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN; IMMUNOHISTOCHEMISTRY; MUTATION; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROTEIN P53; PROTO-ONCOGENE PROTEINS;

EID: 0028815602     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1995.428     Document Type: Article

References (39)

1. BAKER SJ, FEARON ER, NIGRO JM, HAMILTON SR, PREISINGER AC, JESSUP JM, VAN TUINEN P, LEDBETTER DH, BARKER DF, NAKAMURA Y, WHITE R, AND VOGELSTEIN B. (1989). Chromosome 17 deletions and p53 mutations in colorectal carcinoma. Science, 244, 217–221.
2. CAHILLY-SNYDER L, YANG-FENG T, FRANCKE U, AND GEORGE DL. (1987). Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somatic Cell Mol. Genet., 13, 235–244.
3. CORDON-CARDO C, LATRES E, DROBNJAK M, OLIVA MR, POLLACK D, WOODRUFF JM, MARECHAL V, CHEN J, BRENNAN MF, AND LEVINE AJ. (1994). Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res., 54, 794–799.
4. CHEN J, MARECHAL V, AND LEVINE AJ. (1993). Mapping of the p53 and mdm2 interaction domains. Mol. Cell Biol., 13, 4107–4114.
5. DE LA CALLE O, YAGUE J, GAYA A, ROMERO M, AND VIVES J.(1990). Biallelic Bgl II DNA polymorphism of the human p53 oncogene. Nucleic Acids Res., 18, 206.
6. ESTEVE A, LEHMAN T, JIANG W, WEINSTEIN IB, HARRIS CC, RUOL A, PERACCHIA A, MONTESANO R, AND HOLLSTEIN M. (1993). Correlation of p53 mutations with epidermal growth factor over-expression and absence of mdm2 amplification in human esophageal carcinomas. Mol. Carcinogenesis, 8, 306–311.
7. FLORENES VA, MAELANDSMO GM, FORUS A, ANDREASSEN A, MYKELBOST O, AND FODSTAD O. (1994a). MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J. Natl Cancer. Inst., 86, 1297–1302.
8. FLORENES VA, OYJORD T, HOLM R, SKREDE M, BORRESEN AL, NESLAND JM, AND FODSTAD O. (1994b). TP53 allele loss, mutations and expression in malignant melanoma. Br. J. Cancer, 69, 253–259.
9. FOULKES WD, RAGOUSSIS J, STAMP GWH, ALLAN GJ, AND TROWSDALE J. (1993a). Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br. J. Cancer, 67, 551–559.
10. FOULKES WD, BLACK DM, STAMP GWH, SOLOMON E, AND TROWSDALE J. (1993b). Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian cancer. Int. J. Cancer, 54, 220–225.
11. HABUCHI T, KINOSHITA H, YAMADA H, KAKEHI Y, OGAWA O, WU WJ, TAKAHASHI R, SUGIYAMA T, AND YOSHIDA O. (1994). Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J. Natl. Cancer Inst., 86, 1331–1335.
12. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B, AND HARRIS CC.(1991). p53 mutations in human cancer. Science, 253, 49–53.
13. JONES MH, AND NAKAMURA Y. (1992). Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes Chrom. Cancer, 5, 89–90.
14. KESSIS TD, SLEBOS RJ, HAN SM, SHAH K, BOSCH XF, MUNOZ N, HEDRICK L, AND CHO KR. (1993). p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. Am. J. Pathol., 143, 1398–1405.
15. KOHLER MF, KERNS B-JM, HUMPHREY PA, MARKS JR, BAST RC, AND BERCHUCK A. (1993a). Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet. Gynecol., 81, 643–650.
16. KOHLER MF, MARKS JR, WISEMAN RW, JACOBS IJ, DAVIDOFF AM, CLARKE-PEARSON DL, SOPER JT, BAST RC, AND BERCHUCK A. (1993b). Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J. Natl Cancer Inst., 85, 1513–1519.
17. KOVAR H, AUINGER A, JUG G, ARYEE D, ZOUBEK A, SALZERKUNTSCHIK M, AND GADNER H. (1993). Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing’s sarcoma. Oncogene, 8, 2683–2690.
18. KUPRYJANCZYK J, THOR AD, BEAUCHAMP R, MERRITT V, EDGERTON SM, BELL DA, AND YANDELL DW. (1993). p53 gene mutations and protein accumulation in human ovarian cancer. Proc. Natl Acad. Sci. USA, 90, 4961–4965.
19. LADANYI M, CHA C, LEWIS R, JHANWAR SC, HUVOS AG, AND HEALEY JH. (1993). MDM2 gene amplification in metastatic osteocarcinomas. Cancer Res., 53, 16–18.
20. LEACH FS, TOKINO T, METZLER P, BURRELL M, OLINER JD, SMITH S, HILL DE, SIDRANSKY D, KINZLER KW, AND VOGELSTEIN B. (1993). p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res., 53, 2231–2234.
21. LIANES P, ORLOW I, ZHANG ZF, OLIVA MR, SARKIS AS, REUTER VE, AND CORDON-CARDO C. (1994). Altered patterns of MDM2 and TP53 expression in human bladder cancer. J. Natl Cancer. Inst., 86, 1325–1330.
22. MARKS JR, DAVIDOFF AM, KERNS BJ, HUMPHREY PA, PENCE JC, DODGE RK, CLARKE-PETERSON DL, IGLEHART JD, BAST RC, AND BERCHUCK A. (1991). Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res., 61, 2979–2984.
23. MAZARS R, PUJOL P, MAUDELONDE T, JEANTEUR P, AND THEILLET C. (1991). p53 Mutations in ovarian cancer: a later event? Oncogene, 6, 1685–1690.
24. METZLER P. (1994). MDM2 and p53: a question of balance. J. Natl Cancer Inst., 86, 1265–1266.
25. MILNER BJ, ALLAN LA, ECCLES DM, KITCHENER HC, LEONARD RCF, KELLY KF, PARKIN E, AND HAITES NE. (1993). p53 is a common genetic event in ovarian carcinoma. Br. J. Cancer, 53, 2128–2132.
26. MOMAND J, ZAMBETTI GP, OLSON DC, GEORGE DL, AND LEVINE AJ. (1992). The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237–1245.
27. MULLIGAN LM, KWOCK JBJ, HEALEY CS, ELSDON MJ, ENG C, GARDNER E, LOVE DR, MOLE SE, MOORE JK, PAPI L, PONDER MA, TELENIUS H, TUNNACLIFFE A, AND PONDER BAJ. (1993). Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature, 363, 458–460.
28. NIGRO JM, BAKER SJ, PREISINGER AC, JESSUP JM, HOSTETTER R, CLEARY K, BIGNER SH, DAVIDSON N, BAYLIN S, DEVILEE P, GLOVER T, COLLINS FS, WESTON A, MODALI R, HARRIS CC, AND VOGELSTEIN B. (1989). Mutations in the p53 gene occur in diverse human tumour types. Nature, 342, 705–708.
29. OKAMOTO A, SAMESHIMA Y, YOKOYAMA S, TERASHIMA Y, SUGIMARA T, TERADA M, AND YOKOTA J. (1991). Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res., 51, 5171–5176.
30. OLINER JD, KINZLER KW, METZLER PS, GEORGE D, AND VOGELSTEIN B. (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358, 80–83.
31. OLINER JD, PIENTENPOL JA, THIAGALINGAM S, GYURIS J, KINZLER KW, AND VOGELSTEIN B. (1993). Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature, 362, 857–860.
32. PATTERSON H, GIL S, FISHER C, LAW MG, JAYATILAKE H, FLETCHER CDM, THOMAS M, GRIMER R, GUSTERSON BA, AND COOPER CS. (1994). Abnormalities of the p53, MDM2 and DCC genes in human leiomyosarcomas. Br. J. Cancer, 69, 1053–1058.
33. PIGNATELLI M, CARDILLO M, HANBY AN, AND STAMP GWH.(1992). Integrins and their accessory adhesion molecules in mammary carinomas. Human Pathol., 23, 1159–1166.
34. POWIS SH, MOCKRIDGE I, KELLY A, KERR L-A, GLYNNE R, GILEADI U, BECK S, AND TROWSDALE J. (1992). Polymorphism in a second ABC transporter gene located within the class II region of the human major histocompatability complex. Proc. Natl Acad. Sci. USA, 89, 1463–1467.
35. PREUDHOMME C, QUESNEL B, VACHEE A, LEPELLEY P, COLLYND’HOOGHE M, WATTEL E, AND FENAUX P. (1993). Absence of amplication of MDM2 gene, a regulator of p53 function in myelodysplastic syndromes. Leukemia, 7, 1291–1293.
36. REIFENBERGER G, LIU L, ICHIMURA K, SCHMIDT EE, AND COLLINS VP. (1993). Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res., 53, 2736–2739.
37. RIDGE SA, DYER M, GREAVES MF, AND WIEDERMANN LM. (1994). Lack of MDM2 amplification in human leukaemia. Br. J. Haematol., 86, 407–409.
38. TENERIELLO MG, WBINA M, LINNOILA RI, HENRY M, NASH JD, PARK RC, AND BIRRER MJ. (1993). p53 and Ki-ras gene mutations in epithelial ovarian cancer. Cancer Res., 53, 3103–3108.
39. WABER PG, CHEN J, AND NISEN PD. (1993). Infrequency of MDM2 gene amplication in pediatric solid tumours and lack of association with p53 mutations in adult squamous cell carcinomas. Cancer Res., 53, 6028–6030.